SOHO 2021 | Antibody-based therapy in AML: immunotoxins and BiTEs
Amir Fathi, MD, MPH, of Massachusetts General Hospital, Boston, MA, gives an overview of antibody-based therapies in acute myeloid leukemia (AML), immunotoxins and bispecific T-cell engagers (BiTEs). Although antibody-drug conjugates (ADCs) developed for AML such as gemtuzumab ozogamicin as well as newer CD123-targeting ADCs demonstrate a high degree of potency, challenges such as liver toxicity and marrow suppression make its use difficult. Dr Fathi further shares some insights into the efficacy profiles of BiTEs as well as dual-affinity re-targeting antibodies (DARTs) such as flotetuzumab. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
Disclosures
Amir Fathi, MD, MPH, has participated in consultancy work with Pfizer, Trillium, Abbvie, Kura, Blueprint, Genentech, Novartis, Trovagene, Daiichi Sankyo, Novartis, Agios/Servier, BMS, Morphosys, Kite, Foghorn, Takeda, Amgen, Seattle Genetics, NewLink Genetics, Forty Seven and Ipsen; and has received clinical trial support from Agios/Servier, BMS and Abbvie.
